Clinical trial · Interventional
Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients
Phase II Study Evaluating The Role Of Exemestane On Clinical And Pathologic Response Rates, And Its Aromatase Activity As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients.
NCT00174343CI-TRIAL-00004718completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| exemestane (Aromasin®) | Drug | Exemestane | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)
Secondary outcomes (1)
- measure
- To evaluate breast conservative surgery rate; To evaluate intratumoral anti-aromatase activity.
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Post-menopausal patients with unilateral breast cancer T2 to T4, N0-1, M0, non inflammatory, operable, hormonal receptors positive Exclusion Criteria: * Patients with bilateral breast cancer T4d, inflammatory, non operable, hormonal receptors negative
References
Publications (0)
Data not yet available
No reference posted for this study.